Literature DB >> 18509598

Investigations into the formulation of metered dose inhalers of salmeterol xinafoate and fluticasone propionate microcrystals.

Darragh Murnane1, Gary P Martin, Christopher Marriott.   

Abstract

PURPOSE: To investigate the aerosolization and behaviour of microparticles of salmeterol xinafoate (SX) and fluticasone propionate (FP) suspended in hydrofluoroalkane (HFA) propellant.
METHODS: Microcrystals of SX and FP were produced from poly(ethylene glycol) by antisolvent crystallization. The suspension behaviour and aerosolization of the microcrystals when formulated as metered dose inhalers (MDIs) in HFA 134a propellant was compared with that of microparticles produced by micronization (mSX and mFP) using a glass twin stage impinger and by laser light diffraction using a pressurized cell.
RESULTS: FP microparticles underwent non-reversible aggregation in suspension as seen by a doubling in the volume median diameter compared to the raw material. The degree of aggregation of SX particles in suspension was found to decrease as the particle size of the original particles increased. However, because the SX aggregate size was lowest for the particles with the smallest initial size (mSX), the highest fine particle fraction (FPF) of SX was obtained from a suspension of mSX. The FPFs following aerosolization of FP suspensions were similar although the FPF was lowest for particles with the largest original size.
CONCLUSIONS: The size of the aggregates in the HFA suspensions was found to correlate directly with the FPFs determined by impaction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509598     DOI: 10.1007/s11095-008-9622-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

Review 1.  The influence of lung deposition on clinical response.

Authors:  J N Pritchard
Journal:  J Aerosol Med       Date:  2001

2.  Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactose-blend formulations.

Authors:  Margaret D Louey; Michiel Van Oort; Anthony J Hickey
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

3.  Characterization of drug particle surface energetics and young's modulus by atomic force microscopy and inverse gas chromatography.

Authors:  Michael Davies; Anne Brindley; Xinyong Chen; Maria Marlow; Stephen W Doughty; Ian Shrubb; Clive J Roberts
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

4.  Validation of a reverse-phase high performance liquid chromatographic method for concurrent assay of a weak base (salmeterol xinafoate) and a pharmacologically active steroid (fluticasone propionate).

Authors:  D Murnane; G P Martin; C Marriott
Journal:  J Pharm Biomed Anal       Date:  2005-11-08       Impact factor: 3.935

5.  Pharmaceutical transition to non-CFC pressurized metered dose inhalers.

Authors:  A Cripps; M Riebe; M Schulze; R Woodhouse
Journal:  Respir Med       Date:  2000-06       Impact factor: 3.415

6.  Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a.

Authors:  Thomas E Tarara; Michael S Hartman; Howard Gill; Alan A Kennedy; Jeffry G Weers
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

7.  The physico-chemical properties of salmeterol and fluticasone propionate in different solvent environments.

Authors:  Y Michael; B Z Chowdhry; I C Ashurst; M J Snowden; C Davies-Cutting; S Gray
Journal:  Int J Pharm       Date:  2000-05-10       Impact factor: 5.875

8.  Comparison of salmeterol xinafoate microparticle production by conventional and novel antisolvent crystallization.

Authors:  Darragh Murnane; Christopher Marriott; Gary P Martin
Journal:  Eur J Pharm Biopharm       Date:  2007-10-01       Impact factor: 5.571

Review 9.  Inhalation therapy: technological milestones in asthma treatment.

Authors:  Richard Dalby; Julie Suman
Journal:  Adv Drug Deliv Rev       Date:  2003-07-18       Impact factor: 15.470

10.  Manipulation of beclomethasone-hydrofluoroalkane interactions using biocompatible macromolecules.

Authors:  Stuart A Jones; Gary P Martin; Marc B Brown
Journal:  J Pharm Sci       Date:  2006-05       Impact factor: 3.534

View more
  2 in total

Review 1.  Advances in metered dose inhaler technology: formulation development.

Authors:  Paul B Myrdal; Poonam Sheth; Stephen W Stein
Journal:  AAPS PharmSciTech       Date:  2014-01-23       Impact factor: 3.246

2.  Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols.

Authors:  Nashwa El-Gendy; Warangkana Pornputtapitak; Cory Berkland
Journal:  Eur J Pharm Sci       Date:  2011-09-21       Impact factor: 4.384

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.